Evidence map›Paper›PMID 29874243›Full record

ArticlePLoS biology2018

The bench is closer to the bedside than we think: Uncovering the ethical ties between preclinical researchers in translational neuroscience and patients in clinical trials.

Mark Yarborough, Annelien Bredenoord, Flavio D'Abramo, Nanette C Joyce, Jonathan Kimmelman, Ubaka Ogbogu, Emily Sena, Daniel Strech, Ulrich Dirnagl

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Moving towards less biased research.BMJ open science · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Rethinking research reproducibility.The EMBO journal · 2019
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 5 countries.

Mark YarboroughBioethics Program, University of California Davis, Sacramento, California, United States of America.ORCID 0000-0001-8188-4968
Annelien BredenoordJulius Centrum, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.
Flavio D'AbramoDahlem Research School, Freie Universitat Berlin, Berlin, Germany.
Nanette C JoyceBioethics Program, University of California Davis, Sacramento, California, United States of America.
Jonathan KimmelmanStudies of Translation, Ethics, and Medicine (STREAM), Biomedical Ethics Unit, McGill University, Montreal, Canada.
Ubaka OgboguFaculty of Law, University of Alberta, Edmonton, Canada.
Emily SenaCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Daniel StrechInstitute for Ethics, History, and Philosophy of Medicine, Medizinische Hochshule Hannover, Hannover, Germany.
Ulrich DirnaglCharité Universitätsmedizin Berlin, Berlin, Germany.
University of California, Davis · USBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEMax Planck Institute for the History of Science · DEMcGill University · CAMedizinische Hochschule Hannover · DEUniversity Medical Center Utrecht · NLUniversity of Alberta · CAUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Millions of people worldwide currently suffer from serious neurological diseases and injuries for which there are few, and often no, effective treatments. The paucity of effective interventions is, no doubt, due in large part to the complexity of the disorders, as well as our currently limited understanding of their pathophysiology. The bleak picture for patients, however, is also attributable to avoidable impediments stemming from quality concerns in preclinical research that often escape detection by research regulation efforts. In our essay, we connect the dots between these concerns about the quality of preclinical research and their potential ethical impact on the patients who volunteer for early trials of interventions informed by it. We do so in hopes that a greater appreciation among preclinical researchers of these serious ethical consequences can lead to a greater commitment within the research community to adopt widely available tools and measures that can help to improve the quality of research.

Indexed as

AnimalsClinical Trials as TopicHumansNervous System DiseasesNeurosciencesPublication BiasTranslational Research, Biomedical

Identifiers

PMID29874243
PMCPMC6005633
OpenAlexW2805967388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.